Expert in orthopedics

Olivier Jallabert 2

Dear Madam, Dear Sir,

Amplitude Surgical, a leading French player on the global surgical technology market for all lower-limb orthopaedics, was founded in 1997. In France today, our products are used in more than 300 healthcare facilities and we sold over 160 000 prostheses and implants over the past 3 exercises of which more than 60 000 in 2016-17.

Amplitude Surgical continues to implement an active growth strategy thanks to state-of-the-art R&D, major investments and nearly 370 associates eager to open up new markets and introduce new equipment to support medical practitioners and their patients.

In 2016-17, 20 years after its foundation and its second year as a listed company, Amplitude Surgical recorded another year with many key events and a strong growth, with sales exceeding €90 million and an EBITDA margin of almost 17%, two key indicators of our success.

Committed to best meeting the needs of patients, surgeons and healthcare facilities, our main assets are based on an extensive and comprehensive high-end product offer tailored to all surgical philosophies, a substantial ability for high value-added innovation backed by close collaborative relations with renowned surgeons, and the suitability of the products and services we provide.

Being present in more than 30 countries, Amplitude Surgical is recording solid international growth backed by a commercial organization structured around its subsidiaries and a network of exclusive distributors and agents. Both the operational success following the launches of our subsidiaries in Australia and Brazil and funds from our IPO fueled our international growth acceleration.

Thanks to its shareholders, Amplitude Surgical entered a new era. Beyond solid foundations, the potential of the United States – the world’s largest market on which we are developing rapidly – and an innovative product portfolio that is continuously being enhanced will drive our growth and lead to our target of doubling the Group’s sales in 5 years to June 2021 reiterated.”

Olivier Jallabert